Ser40
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser40  -  FRK (human)

Site Information
GALCsPQsQRHGHyF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 34501853

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
luminal B breast cancer ( 1 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , HeLa (cervical) ( 2 ) , liver ( 3 ) , NCI-H3255 (pulmonary) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Rikova K (2012) CST Curation Set: 16146; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info